Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory healthcare trend

Testosterone Therapy for Women Prescription Denials

Analysis based on 7 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The surge in off-label testosterone use and pharmacy friction could boost demand for compounding pharmacies and create opportunities for companies developing women-specific testosterone products. Regulatory attention from the FDA workshop may lead to clearer guidelines, potentially expanding the market but also increasing scrutiny on off-label prescribing.

pharmaceuticals pharmacy retail healthcare

Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023 to July 2026 according to a Truveta analysis for Reuters. Canadian Menopause Society and other medical organizations only endorse testosterone for hypoactive sexual desire disorder in menopausal women. The United States — Food and Drug Administration will hold a public workshop on Thursday to review evidence, promoted by Robert F. Kennedy Jr. and Pete Hegseth. Amazon (company) Pharmacy has rejected some prescriptions requiring customized dosing, citing safety and compliance, while CVS Health says it regularly fills topical testosterone gel prescriptions for women. Walgreens Boots Alliance, Costco, Walmart and Kroger did not respond or declined to comment. Compounded testosterone costs about $100 for a three-month supply versus $30 for a 10-month supply at commercial pharmacies, and most insurers do not cover it. Over 30 trials are underway, including one sponsored by Marius Pharmaceuticals, and Aviva Bio is developing a next-generation product. AbbVie, Upsher-Smith Laboratories and Bicara Therapeutics currently supply branded and generic gels.

60 United States — Food and Drug Administration backed estrogen and progesterone
55 Amazon (company) rejected prescriptions
40 Aviva Bio developing testosterone product
40 Marius Pharmaceuticals sponsored sexual dysfunction trial
20 CVS Health stated pharmacies fill prescriptions
10 Upsher-Smith Laboratories declined to comment
10 Kroger declined to comment
govactor
The FDA is holding a public workshop to review testosterone evidence for menopausal women, which could shape future regulatory approval and market access.
Importance 85.0 Sentiment 10.0
stock
Amazon Pharmacy has rejected some customized testosterone prescriptions, citing safety and compliance, causing patient access issues.
Importance 70.0 Sentiment -10.0
cnt
The U.S. regulatory environment and lack of approved products shape the market for women's testosterone therapy.
Importance 60.0 Sentiment 0.0
ngo
The medical society only endorses testosterone for hypoactive sexual desire disorder, limiting broader clinical acceptance.
Importance 60.0 Sentiment 0.0
stock
CVS states it regularly fills topical testosterone gel prescriptions for women, positioning itself as accommodating.
Importance 50.0 Sentiment 5.0
per
Health Secretary Kennedy has promoted testosterone use for menopausal women, influencing regulatory attention.
Importance 50.0 Sentiment 0.0
stock
AbbVie's AndroGel is among testosterone products used off-label by women, potentially benefiting from increased demand.
Importance 45.0 Sentiment 5.0
per
Dr. Faubion of Mayo Clinic and Canadian Menopause Society cautions on lack of evidence for broader testosterone use in women.
Importance 45.0 Sentiment 0.0
stock
Walgreens did not respond to requests for comment amid reports of prescription issues.
Importance 40.0 Sentiment 0.0
priv
Marius Pharmaceuticals is sponsoring a sexual dysfunction trial for testosterone in women, advancing clinical research.
Importance 40.0 Sentiment 10.0
priv
Aviva Bio is developing a next-generation testosterone product addressing breast cancer risk, targeting the women's market.
Importance 40.0 Sentiment 10.0
per
Defense Secretary Hegseth has raised testosterone levels among troops as an issue, adding political momentum.
Importance 40.0 Sentiment 0.0
priv
Upsher-Smith declined to comment on developing women-specific testosterone products, leaving its strategy unclear.
Importance 35.0 Sentiment 0.0
priv
Keenova's Testim is used off-label by women, but the company did not respond to inquiries.
Importance 35.0 Sentiment 0.0
per
Dr. Stuenkel hopes the FDA will prioritize evaluating a testosterone product designed for women.
Importance 35.0 Sentiment 0.0
+ 5 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.